Inventor · disambiguated record
Abraham Scaria
Also filed as: SCARIA ABRAHAM · SCARIA ABRAHAM VAMATTATHIL
33 granted patents·18 pending applications·251 citations·filing 1997–2025
96Inventor score
Top patents by PatentIndex Score
51 records- 0195US7045508B2Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsGENZYME CORP·Filed 2002·Granted May 16, 2006·35 cites·12 claims
- 0292US7928072B2Multimeric constructsGENZYME CORP·Filed 2007·Granted Apr 19, 2011·21 cites·35 claims
- 0392US6020191AAdenoviral vectors capable of facilitating increased persistence of transgene expressionGENZYME CORP·Filed 1997·Granted Feb 1, 2000·127 cites·3 claims
- 0491US12122998B2Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)CRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 22, 2024·2 cites·22 claims
- 0589US11072792B2Materials and methods for treatment of usher syndrome type 2ACRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 27, 2021·2 cites·16 claims
- 0689US10982228B2AAV vectors for retinal and CNS gene therapyGENZYME CORP·Filed 2015·Granted Apr 20, 2021·4 cites·36 claims
- 0789US10183983B2Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2017·Granted Jan 22, 2019·7 cites·8 claims
- 0888US12241078B2AAV vectors for retinal and CNS gene therapyGENZYME CORP·Filed 2021·Granted Mar 4, 2025·1 cites·37 claims
- 0988US11118177B2Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)CRISPR THERAPEUTICS AG·Filed 2020·Granted Sep 14, 2021·3 cites·2 claims
- 1088US7615537B2Methods for treating blood coagulation disordersGENZYME CORP·Filed 2001·Granted Nov 10, 2009·19 cites·49 claims
- 1188US7307068B2Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsGENZYME CORP·Filed 2005·Granted Dec 11, 2007·3 cites·5 claims
- 1287US10662425B2Materials and methods for treatment of autosomal dominant retinitis pigmentosaCRISPR THERAPEUTICS AG·Filed 2018·Granted May 26, 2020·3 cites·30 claims
- 1387US9637534B2Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2014·Granted May 2, 2017·8 cites·10 claims
- 1486US12215316B2Materials and methods for treatment of usher syndrome type 2ACRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 4, 2025·1 cites·7 claims
- 1580US2025101439A1Materials and methods for controlling gene editingCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1679US10309585B2Light emitting deviceSIGNIFY HOLDING BV·Filed 2014·Granted Jun 4, 2019·4 cites·13 claims
- 1779US2025122497A1Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)CRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1878US8658602B2Multimeric constructsSCARIA ABRAHAM·Filed 2011·Granted Feb 25, 2014·4 cites·28 claims
- 1976US2025283088A1Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2025·Application pending·0 cites
- 2075US11604321B2Light generating system comprising an elongated luminescent bodySIGNIFY HOLDING BV·Filed 2019·Granted Mar 14, 2023·2 cites·15 claims
- 2174US10640771B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2014·Granted May 5, 2020·1 cites·16 claims
- 2272US9815892B2Multimeric constructsGENZYME CORP·Filed 2014·Granted Nov 14, 2017·1 cites·5 claims
- 2372US2022064262A1Fusion proteins comprising pdgf and vegf binding portions and methods of using thereofGENZYME CORP·Filed 2021·Application pending·0 cites
- 2471US12483047B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2022·Granted Nov 25, 2025·0 cites·22 claims
- 2571US7014848B1Enhanced anti-tumor immunityGENZYME CORP·Filed 2000·Granted Mar 21, 2006·2 cites·12 claims
- 2671US2025320522A1Aav vectors for retinal and cns gene therapyGENZYME CORP·Filed 2025·Application pending·0 cites
- 2771US2008096808A1Use of rapamycin to inhibit response and induce tolerance to gene therapy vector and encoded transgene productsSCARIA ABRAHAM·Filed 2007·Application pending·0 cites
- 2869US2024197837A1Gene editing of deep intronic mutationsGENZYME CORP·Filed 2023·Application pending·0 cites
- 2967US12344842B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2020·Granted Jul 1, 2025·0 cites·16 claims
- 3067US12173290B2Materials and methods for controlling gene editingCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 24, 2024·0 cites·28 claims
- 3167US11084864B2Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2018·Granted Aug 10, 2021·0 cites·21 claims
- 3265US8758761B2Combination therapies for treating type 1 diabetesATKINSON MARK A·Filed 2008·Granted Jun 24, 2014·1 cites·16 claims
- 3364US2022340883A1USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTUREGENZYME CORP·Filed 2022·Application pending·0 cites
- 3463US11299715B2Use of iNOS inhibitors to increase viral yield in cultureGENZYME CORP·Filed 2014·Granted Apr 12, 2022·0 cites·9 claims
- 3561US12247201B2Materials and methods for treatment of autosomal dominant retinitis pigmentosaCRISPR THERAPEUTICS AG·Filed 2020·Granted Mar 11, 2025·0 cites·30 claims
- 3661US2011034539A1Methods for treating blood coagulation disordersWADSWORTH SAMUEL·Filed 2009·Application pending·0 cites
- 3760US10995328B2Materials and methods for treatment of autosomal dominant cone-rod dystrophyCRISPR THERAPEUTICS AG·Filed 2020·Granted May 4, 2021·0 cites·16 claims
- 3859US2022081680A1Materials and methods for treatment of autosomal dominant cone-rod dystrophyCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 3958US2018155417A1Multimeric constructsGENZYME CORP·Filed 2017·Application pending·0 cites
- 4058US2002014242A1Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsFiled 2001·Application pending·0 cites
- 4155US2010196401A1Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsGENZYME CORP·Filed 2010·Application pending·0 cites
- 4253US2002019361A1Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsFiled 2001·Application pending·0 cites
- 4348US11896651B2Gene editing of deep intronic mutationsGENZYME CORP·Filed 2016·Granted Feb 13, 2024·0 cites·6 claims
- 4444US10822391B2Fusion proteins and methods for inhibiting IL-17 pathwaysSCARIA ABRAHAM·Filed 2010·Granted Nov 3, 2020·0 cites·1 claims
- 4543US10480733B2Flame simulating light-emitting devices and related methodsSIGNIFY HOLDING BV·Filed 2015·Granted Nov 19, 2019·0 cites·19 claims
- 4643US2004023389A1Adenoviral vectors having nucleic acids encoding immunomodulatory moleculesFiled 2002·Application pending·0 cites
- 4741US10821193B2Adeno-associated viral vectors for treating myocilin (MYOC) glaucomaGENZYME CORP·Filed 2015·Granted Nov 3, 2020·0 cites·61 claims
- 4841US2017007719A1Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2015·Application pending·0 cites
- 4936US2009162345A1Materials and Methods for Reversing Type-1 DiabetesATKINSON MARK A·Filed 2006·Application pending·0 cites
- 5035US2017321867A1Luminaire, luminaire configuration method, computer program product, computing device and lighting systemPHILIPS LIGHTING HOLDING BV·Filed 2015·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Abraham Scaria files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →